We are thrilled to share that Gary Fanger, Chief Executive Officer, from Rise Therapeutics, will be presenting as an Expert Speaker at the 9th Microbiome Movement Drug Development Summit, taking place in Boston, US, from 10 to 12 July. He will also contribute to a panel discussion entitled “Defining Innovative Clinical Strategies Conserving Spend” on July 12th at 9:30 AM at the conference. Download the agenda here: https://lnkd.in/gC3VQTXp #MicrobiomeMovement #Microbiome
Rise Therapeutics’ Post
More Relevant Posts
-
It’s so rewarding knowing that with your work, you can make a difference in the lives of people living with a rare disease. With our marketing efforts, we aim to increase awareness of the disease, improve diagnosis, and ensure patients in need have access to this first available treatment in Europe. Because every single life counts. #rewards #marketing #healthcare #rarediseases #diagnosis
Our most recent partnership with Sentynl Therapeutics, Inc. makes Sciensus the exclusive distribution partner in Europe for NULIBRY, a vital treatment for MoCD Type A. This partnership reflects our ongoing mission to ensure access to essential treatments for patients throughout Europe. To read more about our partnership, visit our website https://lnkd.in/edgU9jVB #rarediseases #orphandrugs #biotechs #patientaccess
To view or add a comment, sign in
-
Listen to Optimum Strategic Communications latest podcast around #clinicaltrials
Diverse recruitment for #clinicaltrials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum Strategic Communications’ Richard Staines as he discuses this thorny issue with Ariceum Therapeutics CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Thought Leader Annalisa Jenkins. 📢 Listen to the latest episode of the #OptimumPerspectivesPodcast now: https://lnkd.in/eEwyCix9 #Ariceum #Leucidbio
To view or add a comment, sign in
-
Check out Optimum's latest podcast featuring an expert panel discussing the issue of diversity in clinical trial recruitment. Thanks to Germo Gericke, Annalisa Jenkins and John Maher for taking part!
Diverse recruitment for #clinicaltrials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum Strategic Communications’ Richard Staines as he discuses this thorny issue with Ariceum Therapeutics CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Thought Leader Annalisa Jenkins. 📢 Listen to the latest episode of the #OptimumPerspectivesPodcast now: https://lnkd.in/eEwyCix9 #Ariceum #Leucidbio
To view or add a comment, sign in
-
As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY
To view or add a comment, sign in
-
As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY
Presentation | Psychedelic Therapeutics & Drug Development Conference
To view or add a comment, sign in
-
This is an impressive application of decision-quality principles very early in biopharma R&D.
New article published in Drug Discovery Today: Making Good Decisions in Early Drug Discovery Our team is excited to share a new article co-authored by Martin Stahl (LifeMine Therapeutics), Virginie Sandrin (Roche), and Bigna Wörsdörfer (Roche) with Ellen Coopersmith and Samuel Vardy of Decision Frameworks. The article shares a proven and effective Decision Quality approach that guides collaborative team discussions to generate alternative discovery advancement plans and qualitatively assess them. The product is a clear decision roadmap for the team to follow and readjust as research progresses. Read the full article here: https://lnkd.in/g_-h2gRq #DecisionMaking #DecisionQuality #DrugDiscovery #Strategy #Uncertainty
To view or add a comment, sign in
-
New article published in Drug Discovery Today: Making Good Decisions in Early Drug Discovery Our team is excited to share a new article co-authored by Martin Stahl (LifeMine Therapeutics), Virginie Sandrin (Roche), and Bigna Wörsdörfer (Roche) with Ellen Coopersmith and Samuel Vardy of Decision Frameworks. The article shares a proven and effective Decision Quality approach that guides collaborative team discussions to generate alternative discovery advancement plans and qualitatively assess them. The product is a clear decision roadmap for the team to follow and readjust as research progresses. Read the full article here: https://lnkd.in/g_-h2gRq #DecisionMaking #DecisionQuality #DrugDiscovery #Strategy #Uncertainty
To view or add a comment, sign in
-
Eli lilly Acquires Morphic Therapeutic for $3.2B 🤝 👉 Eli Lilly will acquire Morphic Holding, a Massachusetts-based biotech company, for $3.2 billion, securing access to an experimental inflammatory bowel disease drug. 👉 Morphic's shares surged 76% pre-market to $56.15 on Lilly's $57 per share offer, a 79% premium to the last closing price. 👉 Morphic's lead drug, MORF-057, is in phase 2 studies for ulcerative colitis and Crohn's disease. The acquisition strengthens Lilly's pipeline in the inflammatory bowel disease treatment market. 💊
To view or add a comment, sign in
-
Hot of the Press! It’s been publications galore in the RAS world in 2024 and the past week has been no exception. Luckily enough, first and best-in-class therapies for CRC, pan-RAS approaches and non-canonical targets will be the hot topics filled with BRAND NEW DATA, exclusively at the 6th Annual RAS-Targeted Drug Development Summit (September 24 – 26, Boston, MA). Peers from Revolution Medicines, Amgen, Loxo@Lilly, Roche, GenFleet Therapeutics, Nested Therapeutics, Astellas Pharma, and 40+ more organizations are uniting to improve the standard of care for patients with unmet needs. Download the brochure now to see our topics of choice and find out how to join them: https://ter.li/8vhngl References: https://lnkd.in/eqznq5rM https://lnkd.in/eHYFStQE
To view or add a comment, sign in
-
As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY
Presentation | Psychedelic Therapeutics & Drug Development Conference
To view or add a comment, sign in
1,886 followers
Vice President Operations
4moDon't miss it!